Immunoglobulin Patents (Class 536/23.53)
-
Publication number: 20140245468Abstract: Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence. Also described are genetically modified non-human animals comprising an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, which may be operably linked to a light chain constant region nucleic acid sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a heavy chain.Type: ApplicationFiled: February 20, 2014Publication date: August 28, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Cagan Gurer, Karolina A. Meagher, Lynn Macdonald, Andrew J. Murphy
-
Patent number: 8815238Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.Type: GrantFiled: August 1, 2013Date of Patent: August 26, 2014Assignee: ZymoGenetics, Inc.Inventors: Mark W. Rixon, Jane A. Gross
-
Patent number: 8816058Abstract: Isolated polynucleotides are provided which encode antibody VH and VL polypeptides, and anti-CD100 antibodies and antigen-binding fragments thereof. In another aspect, the invention provides a vector comprising a polynucleotide of the invention. In another aspect, the invention provides a host cell comprising the vector of the invention. In another aspect, the invention provides a method of producing an antibody of the invention, e.g., for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers.Type: GrantFiled: June 14, 2012Date of Patent: August 26, 2014Assignee: Vaccinex, Inc.Inventors: Ernest S. Smith, Terrence Lee Fisher
-
Publication number: 20140235476Abstract: Provided are protein, nucleic acid, and cellular libraries of multivalent binding proteins (e.g., DVD-Fab or DVD-Ig molecules) and the use of these libraries for the screening of multivalent binding proteins using cell surface display technology (e.g., yeast display).Type: ApplicationFiled: December 27, 2013Publication date: August 21, 2014Applicant: AbbVie, Inc.Inventors: Jijie GU, Maria Cristina HARRIS, Lorenzo BENATUIL, Chung-Ming HSIEH
-
Publication number: 20140234297Abstract: The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more FcRs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region.Type: ApplicationFiled: September 24, 2013Publication date: August 21, 2014Inventor: Genevieve HANSEN
-
Publication number: 20140235843Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.Type: ApplicationFiled: January 24, 2014Publication date: August 21, 2014Applicant: arGEN-X B.V.Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
-
Publication number: 20140234331Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.Type: ApplicationFiled: April 28, 2014Publication date: August 21, 2014Applicant: Medarex, L.L.C.Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
-
Publication number: 20140235833Abstract: The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: FUJITA HEALTH UNIVERSITYInventors: Atsushi SUGIOKA, Gene KUROSAWA, Mariko SUMITOMO, Yoshikazu KUROSAWA
-
Publication number: 20140234336Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
-
Publication number: 20140234213Abstract: Methods for generating hybrid antibodies are provided.Type: ApplicationFiled: May 29, 2012Publication date: August 21, 2014Inventors: Gregory P. Adams, Heidi H. Simmons, Matthew K. Robinson, Roland Dunbrack, Andreas Lehmann
-
Publication number: 20140234315Abstract: scFv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with CDRs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scFv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scFV that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scFv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: ESBATECH, an Alcon Biomedical Research Unit LLCInventors: Adrian Auf Der Maur, Alcide Barberis, David M. Urech, Peter Lichtlen
-
Publication number: 20140234344Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: ApplicationFiled: January 27, 2014Publication date: August 21, 2014Applicant: Baylor Research InstituteInventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
-
Patent number: 8809017Abstract: This invention relates to nucleic acid molecules comprising at least one nucleic acid sequence encoding for a peptide or protein of interest, at least one nucleic acid sequence encoding for a selectable marker, and at least one IRES sequence, wherein the at least one IRES sequence is located between the at least one nucleic acid sequence encoding for the peptide or protein of interest and the at least one nucleic acid sequence encoding for the selectable marker. Furthermore, this invention relates to host cells comprising such nucleic acid molecule and to methods of recombinant protein expression using such host cells.Type: GrantFiled: May 24, 2012Date of Patent: August 19, 2014Assignee: Agency for Science, Technology and ResearchInventors: Yuansheng Yang, Steven Ho, Jia Juan Lee
-
Publication number: 20140227291Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.Type: ApplicationFiled: August 12, 2011Publication date: August 14, 2014Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giasi, Ulrich Ebert, Chung-Ming Hsieh
-
Publication number: 20140227251Abstract: The disclosure describes methods of identifying a variant of a reference antibody with reduced immunogenicity as compared to the reference antibody. The disclosure further describes variants of a reference anti-TNF-? antibody having reduced immunogenicity as compared to the reference anti-TNF-? reference antibody.Type: ApplicationFiled: September 18, 2013Publication date: August 14, 2014Applicant: AbbVie Biotherapeutics Inc.Inventors: Fiona A. HARDING, Olivia Jennifer Razo
-
Publication number: 20140227270Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumour growth.Type: ApplicationFiled: March 28, 2012Publication date: August 14, 2014Inventors: Francis Descamps, David André Baptiste Maussang-Detaille, Maarten Van Roy, Regorius Leurs, Maria Gonzalez Pajuelo, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
-
Publication number: 20140227283Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.Type: ApplicationFiled: June 22, 2012Publication date: August 14, 2014Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Regional du Cancer de Montpellier-Val d'Aurelle, UNIVERSITE DE MONTPELLIER 1, OriBase PharmaInventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Publication number: 20140227258Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.Type: ApplicationFiled: March 14, 2014Publication date: August 14, 2014Applicant: Genentech, Inc.Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
-
Publication number: 20140227294Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).Type: ApplicationFiled: December 23, 2013Publication date: August 14, 2014Applicant: ABBVIE INC.Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. DiGiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
-
Publication number: 20140227259Abstract: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.Type: ApplicationFiled: August 13, 2012Publication date: August 14, 2014Applicant: Glaxo Group LimitedInventors: Claire Ashman, Mary Birchler, Rudolf M.T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
-
Publication number: 20140227287Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as the effects on a fetus, thrombus formation, and joint-related adverse events such as RPOA while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence represented by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence represented by SEQ ID NO:4.Type: ApplicationFiled: February 8, 2013Publication date: August 14, 2014Applicant: Astellas Pharma Inc.Inventors: Masazumi KAMOHARA, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Publication number: 20140227257Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: February 14, 2014Publication date: August 14, 2014Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun CHEN, Stephen H. LEPPLA, Mahtab MOAYERI, Suzanne U. EMERSON, Robert H. PURCELL
-
Publication number: 20140227273Abstract: Described are proteinaceous molecules comprising at least two, preferably three to six, binding domains that bind specifically to at least two different binding sites on aberrant cells. These multi-domain and multi-specific binding molecules are preferably used in selectively modulating biological processes. The provided binding molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.Type: ApplicationFiled: September 26, 2012Publication date: August 14, 2014Applicant: APO-TB.V.Inventors: Ralph Alexander Willemsen, Johan Renes
-
Publication number: 20140219919Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.Type: ApplicationFiled: February 6, 2014Publication date: August 7, 2014Applicant: CSL LimitedInventors: Kirsten EDWARDS, Matthew HARDY, Veronika RAYZMAN, Michael WILSON
-
Publication number: 20140220027Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: April 14, 2014Publication date: August 7, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20140220045Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.Type: ApplicationFiled: February 7, 2014Publication date: August 7, 2014Applicant: NANOONCOLOGY, INC.Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
-
Publication number: 20140221621Abstract: Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).Type: ApplicationFiled: December 27, 2013Publication date: August 7, 2014Applicant: AbbVie, Inc.Inventors: Lorenzo BENATUIL, Chung-Ming HSIEH
-
Publication number: 20140220634Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.Type: ApplicationFiled: February 6, 2013Publication date: August 7, 2014Applicant: Janssen Biotech, Inc.Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
-
Publication number: 20140219913Abstract: Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: December 27, 2013Publication date: August 7, 2014Applicant: AbbVie, Inc.Inventors: Tariq Ghayur, Philip Bardwell
-
Publication number: 20140221620Abstract: It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in SEQ ID NO: 38 that is the extracellular region of human CDH3, and has cytotoxicity against CDH3-expressing cells.Type: ApplicationFiled: June 19, 2012Publication date: August 7, 2014Applicant: PERSEUS PROTEOMICS INC.Inventors: Lilin Zhang, Katsuyuki Mimoti, Katsushi Kouda, Yoko Kayukawa
-
Publication number: 20140220031Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.Type: ApplicationFiled: December 19, 2013Publication date: August 7, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Herman Van Vlijmen, Alexey Alexandrovic Lugovskoy, Karl J.M. Hanf
-
Publication number: 20140220019Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: ApplicationFiled: December 19, 2013Publication date: August 7, 2014Applicant: AbbVie, Inc.Inventors: Tariq GHAYUR, Junjian LIU, Peter C. ISAKSON
-
Publication number: 20140220026Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.Type: ApplicationFiled: March 21, 2014Publication date: August 7, 2014Applicant: GENEURO SAInventors: Corinne BERNARD, Alois Bernhardt LANG, Herve PERRON, Jean-Baptiste BERTRAND
-
Publication number: 20140219912Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: ApplicationFiled: December 19, 2013Publication date: August 7, 2014Applicant: AbbVie, Inc.Inventors: Tariq GHAYUR, Junjian LIU, Peter C. ISAKSON
-
Publication number: 20140220040Abstract: Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing.Type: ApplicationFiled: April 17, 2014Publication date: August 7, 2014Applicant: ARCA BIOPHARMA, INC.Inventors: Arie Abo, Minke Binnerts
-
Publication number: 20140220008Abstract: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.Type: ApplicationFiled: February 10, 2014Publication date: August 7, 2014Applicant: BIOTEST AGInventors: John Wijdenes, Helmut Jonuleit
-
Publication number: 20140223591Abstract: The present disclosure generally relates to methods and compositions for contraception. In some embodiments, vector based approaches for contraception are provided.Type: ApplicationFiled: January 31, 2014Publication date: August 7, 2014Applicant: California Institute of TechnologyInventors: Bruce A. Hay, Juan Li
-
Patent number: 8796439Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.Type: GrantFiled: August 7, 2012Date of Patent: August 5, 2014Assignees: AC Immune S.A., Genetech, Inc.Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20140212431Abstract: The invention provides PCSK9-binding polypeptides and methods of using the same.Type: ApplicationFiled: December 19, 2013Publication date: July 31, 2014Applicant: GENENTECH, INC.Inventors: Daniel K. Kirchhofer, Yingnan Zhang, Andrew Scott Peterson, Wei Li, Monica Kong-Beltran, Lijuan Zhou
-
Publication number: 20140212424Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.Type: ApplicationFiled: February 28, 2014Publication date: July 31, 2014Applicant: AbbVie Biotherapeutics Inc.Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
-
Publication number: 20140212429Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: April 16, 2014Publication date: July 31, 2014Applicant: MEDIMMUNE LIMITEDInventors: JAMIE IAIN CAMPBELL, DUNCAN JAMES COCHRANE, DONNA KIRSTY FINCH, MARIA ANASTASIA TERESA GROVES, DAVID CHRISTOPHER LOWE, SIMON CHARLES CRUWYS
-
Publication number: 20140212925Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.Type: ApplicationFiled: December 17, 2013Publication date: July 31, 2014Applicant: AbbVie, Inc.Inventors: Chengbin WU, Dominic J. AMBROSI, Chung-ming HSIEH, Tariq GHAYUR
-
Publication number: 20140212439Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.Type: ApplicationFiled: May 22, 2013Publication date: July 31, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Jun Hasegawa, Toshiaki Ohtsuka, Atsushi Urano, Junko Yamaguchi, Toshinori Agatsuma, Kaori Nakahara, Takeshi Takizawa
-
Publication number: 20140212896Abstract: All neoplastic cells express one or more members of a unique family of cell surface ubiquinone (NADH) oxidase proteins with protein disulfide-thiol interchange activity (ECTO-NOX proteins) that are characteristically inhibited by quinone site inhibitors with anti-cancer activity and a common amino acid sequence disclosed herein that allows for cancer-specific antibody recognition as well as for detection of certain critical reference proteins that provide loading controls. Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Mor-NuTech, Inc.Inventors: D. James Morrè, Brandon Eugene Hostetler, James Jinpal Kim
-
Publication number: 20140212408Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.Type: ApplicationFiled: December 20, 2013Publication date: July 31, 2014Applicant: ROCHE GLYCART AGInventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
-
Publication number: 20140212416Abstract: The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies comprising human variable region sequences. The present invention is directed to the provision of long HCDR3s from non-human vertebrates and cells. The present invention is also directed to the provision of novel V, D and J pairings in immunoglobulin heavy and light chain loci. Novel, biased antibody diversities and potentially expanded diversities are provided. The invention also provides for novel and potentially expanded diversity or diversity that is biased towards variable gene usage common to antibodies useful for treating and/or preventing certain diseases or conditions, such as infectious diseases. The invention also provides methods of generating antibodies using such vertebrates, as well as the antibodies per se, therapeutic compositions thereof and uses.Type: ApplicationFiled: March 19, 2014Publication date: July 31, 2014Applicant: Kymab LimitedInventors: Glenn Friedrich, E-Chiang Lee, Jasper Clube, Nicholas England
-
Publication number: 20140212423Abstract: Engineered multivalent and multispecific binding proteins capable of penetrating the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: December 4, 2013Publication date: July 31, 2014Applicant: ABBVIE, INC.Inventors: Denise KARAOGLU HANZATIAN, Tariq GHAYUR, Annette J. SCHWARTZ STERMAN, Andrew GOODEARL, Maria Cristina HARRIS
-
Patent number: 8791249Abstract: This invention relates to compositions and methods for treating c-Kit associated disorders such as fibrosis, and more particularly, to compositions containing humanized c-Kit antibodies.Type: GrantFiled: May 6, 2013Date of Patent: July 29, 2014Assignee: Amgen Inc.Inventors: Gordon Ng, Wenyan Shen
-
Patent number: 8790644Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.Type: GrantFiled: January 25, 2013Date of Patent: July 29, 2014Assignee: Neotope Biosciences LimitedInventors: Jose Saldanha, Tarlochan S. Nijjar
-
Publication number: 20140206579Abstract: A synthetic DNA library or a member of a synthetic DNA library of antibodies or fragments of antibody molecules having heavy chain(s) and lacking light chain(s) is described wherein the CDR within variable domains are synthesized using randomly assembled trinucleotide phosphoramidites (trimer phosphoramidites) to eliminate unwanted cysteine amino acids and/or stop codons.Type: ApplicationFiled: August 20, 2013Publication date: July 24, 2014Applicant: Syndecion, LLCInventors: Alan D. KING, Stephen B. DEITZ